Project leadersJesús Garcia-Gil, Xavier Aldeguer, Mariona Serra
Participating organizationsUniversity of Girona (UdG), Girona Biomedical Research Institute (IDIBGI)
To develop support systems for diagnosing and treating digestive diseases through the study of the intestinal microbiota. The company has three product lines: RAID-CRC (early detection of colorectal cancer), RAID-CD (diagnosing irritable bowel, Crohn's disease and ulcerative colitis) and PREVIPECT (prebiotic to treat digestive diseases).
From the University of Girona, Professor of Microbiology Jesús Garcia-Gil has contributed expertise in microbiology of ecosystems. Additionally, from the Girona Biomedical Research Institute (IDIBGI), Dr. Xavier Aldeguer, head of the Digestive System Unit at Hospital Doctor Josep Trueta, has contributed clinical knowledge of digestive diseases.
Most significant challenges
The most important challenge of GoodGut has been to not lose sight of the market when developing products, as they tend to take more than a year of development and, over this time, the market and regulatory issues can change. The team highlights the need to "plan to improvise", meaning you have to think of all possible scenarios to minimize the risk associated with developing your projects. Planning the project from beginning to market launch has been key to tackling the changes that have popped up, as has revising that plan periodically.
GoodGut has received funding from several sources: the NEOTEC program from the Center for the Development of Industrial Technology (CDTI), the Ministry of the Economy and Competitiveness Retos program, MERCAT grants from the Agency for Administration of University and Research Grants (AGAUR), IFEM microloans from the Catalan Institute of Finance (ICF), the Girona Regional Council and Industrial doctorates.
GoodGut has currently submitted 5 patent applications for its 3 products. The company will begin a clinical validation study in Germany with 2,800 patients on RAID-CRC (early detection of colorectal cancer), which will allow it to hit the market sometime in 2019. With regard to RAID-CD (diagnosing irritable bowel, Crohn's disease and ulcerative colitis), the company is finishing up clinical studies that will allow it to get CE marking by the end of 2018. For PREVIPECT (prebiotic to treat digestive diseases), the company has finished proof of concept and is starting toxicity studies prior to the clinical trial.